Duchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2019

GlobalData's clinical trial report, “Duchenne Muscular Dystrophy Global Clinical Trials Review, H1, 2019" provides an overview of Duchenne Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

PTC Therapeutics Inc

Sarepta Therapeutics Inc

BioMarin Pharmaceutical Inc

GlaxoSmithKline Plc

Summit Therapeutics Plc

ReveraGen BioPharma Inc

Catabasis Pharmaceuticals Inc

Akashi Therapeutics Inc

Santhera Pharmaceuticals ...

PTC Therapeutics Inc

Sarepta Therapeutics Inc

BioMarin Pharmaceutical Inc

GlaxoSmithKline Plc

Summit Therapeutics Plc

ReveraGen BioPharma Inc

Catabasis Pharmaceuticals Inc

Akashi Therapeutics Inc

Santhera Pharmaceuticals Holding AG

Prosensa Holding B.V. (Inactive)

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region ...

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 27

In Progress Trials by Phase 28

Clinical Trials by Trial Status 29

Clinical Trials by End Point Status 31

Subjects Recruited Over a Period of Time 32

Clinical Trials by Sponsor Type 33

Prominent Sponsors 34

Top Companies Participating in Duchenne Muscular Dystrophy Therapeutics Clinical Trials 36

Prominent Drugs 38

Latest Clinical Trials News on Duchenne Muscular Dystrophy 39

May 02, 2019: Catabasis Pharmaceuticals to present data from the MoveDMD trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting 39

Apr 20, 2019: Catabasis opens new UK sites in Edasalonexent trial 39

Apr 16, 2019: Wave Life Sciences announces Suvodirsen phase 1 safety and tolerability data and phase 2/3 clinical trial design 39

Apr 15, 2019: Santhera to Present Long-term efficacy results with Idebenone in DMD at the 2019 MDA Clinical and Scientific Conference 40

Apr 12, 2019: Wave Life Sciences to host investor conference call to discuss Suvodirsen DMD clinical data being presented at MDA Clinical and scientific conference 41

Apr 04, 2019: Antisense Therapeutics provides update on its phase II clinical trial in Duchenne Muscular Dystrophy 41

Apr 01, 2019: Catabasis Pharmaceuticals to present at upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference 42

Mar 28, 2019: Sarepta Therapeutics announces positive expression results from the Casimersen (SRP-4045) arm of the ESSENCE study 42

Mar 25, 2019: Wave Life Sciences to present Suvodirsen phase 1 safety and tolerability data and phase 2/3 clinical trial design at the muscular dystrophy association clinical and scientific conference 43

Mar 25, 2019: Sarepta Therapeutics to provide update on Duchenne Muscular Dystrophy gene therapy program 44

Feb 26, 2019: Santhera reports positive data from idebenone trial in DMD patients 44

Feb 19, 2019: Catabasis Pharmaceuticals presents data supporting Edasalonexent as a potential foundational treatment for Duchenne Muscular Dystrophy 44

Clinical Trial Profile Snapshots 46

Appendix 202

Abbreviations 202

Definitions 202

Research Methodology 203

Secondary Research 203

About GlobalData 204

Contact Us 204

Source 205

List of Tables

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2019* 8

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* ...

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2019* 8

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries, 2019* 14

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 15

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries, 2019* 16

Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2019* 17

Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2019* 22

Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase, 2019* 27

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 28

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32

Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 33

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

List of Figures

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, ...

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 15

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019* 16

Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2019* 17

Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2019* 22

Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2019* 27

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 28

Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32

Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 33

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36

Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

GlobalData Methodology 203

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports